DICE Therapeutics Inc (DICE) Stock Price, Quote, News and Overview
NASDAQ:DICE - Nasdaq - US23345J1043 - Common Stock - Currency: USD
DICE Quote, Performance and Key Statistics
47.55
+0.03 (+0.06%)
The current stock price of DICE is 47.55 USD. In the past month the price increased by 1.67%. In the past year, price increased by 136.1%.
DICE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About DICE
Company Profile
DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2021-09-15. The firm is focused on developing oral therapeutics against well-validated targets in immunology. The firm's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The firm's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The firm is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
Company Info
DICE Therapeutics Inc
400 East Jamie Court, Suite 300
South San Francisco CALIFORNIA US
CEO: J. Kevin Judice
Employees: 81
Company Website: https://www.dicetherapeutics.com/
Phone: 16505661402.0
DICE Therapeutics Inc / DICE FAQ
What is the stock price of DICE Therapeutics Inc today?
The current stock price of DICE is 47.55 USD. The price increased by 0.06% in the last trading session.
What is the ticker symbol for DICE Therapeutics Inc stock?
The exchange symbol of DICE Therapeutics Inc is DICE and it is listed on the Nasdaq exchange.
On which exchange is DICE stock listed?
DICE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DICE Therapeutics Inc stock?
14 analysts have analysed DICE and the average price target is 50.36 USD. This implies a price increase of 5.91% is expected in the next year compared to the current price of 47.55. Check the DICE Therapeutics Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DICE Therapeutics Inc worth?
DICE Therapeutics Inc (DICE) has a market capitalization of 2.27B USD. This makes DICE a Mid Cap stock.
How many employees does DICE Therapeutics Inc have?
DICE Therapeutics Inc (DICE) currently has 81 employees.
What are the support and resistance levels for DICE Therapeutics Inc (DICE) stock?
DICE Therapeutics Inc (DICE) has a support level at 47.23 and a resistance level at 47.56. Check the full technical report for a detailed analysis of DICE support and resistance levels.
Should I buy DICE Therapeutics Inc (DICE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DICE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DICE, evaluating the profitability, health, valuation and growth aspects
- DICE Therapeutics Inc (DICE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DICE Therapeutics Inc (DICE) Sales and EPS estimates to see what analysts future expectations are.
- DICE Therapeutics Inc (DICE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DICE Therapeutics Inc (DICE) Insider and Institutional Ownership to learn about the owners and their transactions.
- DICE Therapeutics Inc (DICE) Stock Chart to make your own analysis
- DICE Therapeutics Inc (DICE) Latest news and press-releases to stay up to date.
Does DICE Therapeutics Inc (DICE) stock pay dividends?
DICE does not pay a dividend.
What is the Price/Earnings (PE) ratio of DICE Therapeutics Inc (DICE)?
DICE Therapeutics Inc (DICE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.18).
DICE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DICE. When comparing the yearly performance of all stocks, DICE is one of the better performing stocks in the market, outperforming 98.59% of all stocks.
DICE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DICE. While DICE has a great health rating, there are worries on its profitability.
DICE Financial Highlights
Over the last trailing twelve months DICE reported a non-GAAP Earnings per Share(EPS) of -2.18. The EPS decreased by -20.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DICE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 53% to DICE. The Buy consensus is the average rating of analysts ratings from 14 analysts.